marketcaparena
Search

    NAGE

    Niagen Bioscience, Inc.

    Company overview

    Market capitalization
    $235.80M
    Employees
    117
    Latest publication
    2026-09-29
    About Niagen Bioscience, Inc.

    Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue29,785,000USD31,474,000USD33,839,000USD33,986,000USD31,117,000USD30,481,000USD29,125,000USD25,580,000USD
    Cost Of Revenue10,471,000USD11,498,000USD12,135,000USD12,058,000USD10,891,000USD11,150,000USD10,928,000USD9,340,000USD
    Gross Profit19,314,000USD19,976,000USD21,704,000USD21,928,000USD20,226,000USD19,331,000USD18,197,000USD16,240,000USD
    Research Development1,513,000USD1,481,000USD1,710,000USD1,795,000USD1,567,000USD1,258,000USD1,315,000USD1,290,000USD
    Selling And Marketing Expenses10,130,000USD9,675,000USD10,414,000USD8,768,000USD8,207,000USD8,117,000USD8,716,000USD7,044,000USD
    General And Administrative Expenses6,971,000USD———————
    Total Operating Expenses18,614,000USD18,400,000USD19,601,000USD17,692,000USD17,041,000USD14,559,000USD11,086,000USD14,638,000USD
    Operating Income700,000USD1,576,000USD2,103,000USD4,236,000USD3,185,000USD4,772,000USD7,111,000USD1,602,000USD
    Total Other Income Expense Net369,000USD5,159,000USD2,321,000USD564,000USD552,000USD459,000USD373,000USD276,000USD
    Income Before Tax1,069,000USD6,735,000USD4,424,000USD4,800,000USD3,737,000USD5,231,000USD7,484,000USD1,878,000USD
    Income Tax Expense106,000USD417,000USD292,000USD222,000USD128,000USD168,000USD305,000USD—
    Net Income963,000USD6,318,000USD4,131,999USD4,578,000USD3,609,000USD5,063,000USD7,179,000USD1,878,000USD
    Selling General Administrative—7,244,000USD7,477,000USD7,129,000USD7,267,000USD5,184,000USD1,055,000USD6,304,000USD
    Interest Income—375,000USD552,000USD564,000USD552,000USD459,000USD373,000USD276,000USD
    Net Interest Income—375,000USD552,000USD564,000USD552,000USD459,000USD373,000USD276,000USD
    Tax Provision—417,000USD292,000USD222,000USD128,000USD168,000USD——
    Net Income From Continuing Ops—6,318,000USD4,132,000USD4,578,000USD3,609,000USD5,063,000USD7,179,000USD1,878,000USD
    Ebit—6,735,000USD4,424,000USD4,800,000USD3,737,000USD5,231,000USD7,484,000USD1,878,000USD
    Ebitda—7,026,000USD5,288,000USD4,995,000USD4,092,000USD5,599,000USD7,842,000USD2,244,000USD
    Depreciation And Amortization—291,000USD864,000USD195,000USD355,000USD368,000USD358,000USD366,000USD
    Reconciled Depreciation—464,000USD368,000USD359,000USD355,000USD368,000USD358,000USD366,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20092009-12-31 · USDFY 20072007-12-31 · USD
    Total Revenue129,423,000USD99,597,000USD5,777,865USD—
    Cost Of Revenue46,234,000USD38,011,000USD3,736,435USD—
    Gross Profit83,189,000USD61,586,000USD2,041,430USD—
    Research Development6,330,000USD6,016,000USD——
    Selling General Administrative27,057,000USD18,375,000USD2,104,193USD—
    Selling And Marketing Expenses35,506,000USD29,469,000USD829,969USD—
    Total Operating Expenses68,893,000USD53,860,000USD2,934,162USD38,382USD
    Operating Income14,296,000USD7,726,000USD-892,732USD-38,382USD
    Interest Income2,127,000USD1,129,000USD——
    Net Interest Income2,127,000USD1,129,000USD——
    Income Before Tax18,192,000USD8,855,000USD——
    Income Tax Expense810,000USD305,000USD907,568USD38,382USD
    Tax Provision810,000USD305,000USD——
    Net Income17,382,000USD8,550,000USD-907,568USD-38,382USD
    Net Income From Continuing Ops17,382,000USD8,550,000USD——
    Ebit18,192,000USD8,855,000USD-892,732USD—
    Ebitda19,642,000USD10,339,000USD-498,232USD-38,382USD
    Depreciation And Amortization1,450,000USD1,484,000USD394,500USD—
    Reconciled Depreciation1,450,000USD1,484,000USD——
    Total Other Income Expense Net3,896,000USD1,129,000USD892,732USD38,382USD
    Interest Expense——17,090USD—
    Other Operating Expenses———38,382USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets106,589,000USD114,329,000USD106,406,000USD98,139,000USD91,525,000USD81,337,000USD68,278,000USD56,522,000USD
    Cash And Equivalents66,740,000USD———————
    Total Current Assets97,786,000USD105,121,000USD96,806,000USD93,616,000USD86,679,000USD76,218,000USD64,102,000USD52,134,000USD
    Other Current Assets1,826,000USD1,488,000USD1,853,000USD2,181,000USD2,295,000USD2,517,000USD2,634,000USD2,248,000USD
    Other Non Current Assets405,000USD———————
    Total Liabilities24,061,000USD———————
    Total Current Liabilities15,050,000USD22,824,000USD19,919,000USD22,712,000USD22,327,000USD20,837,000USD17,948,000USD17,699,000USD
    Other Current Liabilities3,841,000USD———————
    Total Stockholder Equity82,528,000USD82,330,000USD76,533,000USD70,676,000USD64,195,000USD55,345,000USD46,094,000USD34,369,000USD
    Total Equity Including Noncontrolling Interest82,528,000USD———————
    Deferred Revenue Non Current2,434,000USD———————
    Net Receivables8,580,000USD13,068,000USD9,741,000USD8,506,000USD9,656,000USD7,052,000USD7,768,000USD7,096,000USD
    Property Plant Equipment Net3,087,000USD3,317,000USD3,515,000USD3,860,000USD4,157,000USD4,339,000USD3,449,000USD3,617,000USD
    Intangible Assets5,311,000USD5,485,000USD5,660,000USD246,000USD284,000USD322,000USD359,000USD397,000USD
    Accounts Payable9,439,000USD13,277,000USD10,796,000USD12,742,000USD13,680,000USD10,632,000USD8,526,000USD6,903,000USD
    Short Term Debt917,000USD1,032,000USD1,002,000USD978,000USD963,000USD948,000USD994,000USD1,020,000USD
    Common Stock79,000USD79,000USD79,000USD79,000USD79,000USD78,000USD77,000USD76,000USD
    Retained Earnings-157,247,000USD-158,210,000USD-164,528,000USD-168,660,000USD-173,238,000USD-176,847,000USD-181,910,000USD-189,089,000USD
    Total Liab—31,999,000USD29,873,000USD27,463,000USD27,330,000USD25,992,000USD22,184,000USD22,153,000USD
    Other Current Liab—8,515,000USD8,121,000USD8,992,000USD7,381,000USD9,050,000USD7,817,000USD9,592,000USD
    Capital Stock—79,000USD79,000USD79,000USD79,000USD78,000USD77,000USD76,000USD
    Cash—66,549,000USD64,788,000USD64,138,000USD60,322,000USD55,464,000USD44,508,000USD32,246,000USD
    Cash And Short Term Investments—66,549,000USD64,788,000USD64,138,000USD60,322,000USD55,464,000USD44,508,000USD32,246,000USD
    Net Debt—-63,973,000USD-61,971,000USD-61,083,000USD-57,030,000USD-51,940,000USD-41,857,000USD-29,351,000USD
    Short Long Term Debt Total—2,576,000USD2,817,000USD3,055,000USD3,292,000USD3,524,000USD2,651,000USD2,895,000USD
    Inventory—24,016,000USD20,424,000USD18,791,000USD14,406,000USD11,185,000USD9,192,000USD10,544,000USD
    Property Plant Equipment Gross—3,317,000USD9,269,000USD3,860,000USD4,157,000USD4,339,000USD9,213,000USD3,617,000USD
    Accumulated Other Comprehensive Income—-3,000USD-9,000USD-8,999USD-4,000USD-5,000USD-4,000USD-7,000USD
    Common Stock Shares Outstanding—84,566,000shares84,444,000shares86,619,000shares86,241,000shares83,232,000shares81,681,000shares77,768,000shares
    Non Current Assets Total—9,207,999USD9,600,000USD4,523,000USD4,846,000USD5,119,000USD4,176,000USD4,388,000USD
    Non Current Liabilities Total—9,174,999USD9,954,000USD4,751,000USD5,003,000USD5,155,000USD4,236,000USD4,454,000USD
    Non Currrent Assets Other—405,999USD425,000USD417,000USD405,000USD458,000USD368,000USD374,000USD
    Net Working Capital—82,297,000USD76,887,000USD70,904,000USD64,352,000USD55,381,000USD46,154,000USD34,435,000USD
    Unclassified Non Current Liabilities—9,174,999USD9,954,000USD4,751,000USD5,003,000USD5,155,000USD4,236,000USD4,454,000USD
    Unclassified Equity—240,385,000USD240,912,000USD239,186,999USD237,279,000USD232,041,000USD227,854,000USD223,313,000USD
    Current Deferred Revenue————303,000USD207,000USD611,000USD184,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets106,406,000USD68,278,000USD54,964,000USD54,057,000USD57,840,000USD38,358,000USD40,247,000USD42,232,000USD
    Intangible Assets5,660,000USD359,000USD510,000USD671,000USD857,000USD1,082,000USD1,311,000USD1,547,000USD
    Other Current Assets1,853,000USD2,634,000USD2,602,000USD3,119,000USD2,059,000USD1,345,000USD1,196,000USD1,454,000USD
    Total Liab29,873,000USD22,184,000USD26,508,000USD25,385,000USD26,113,000USD21,934,000USD19,802,000USD15,054,000USD
    Total Stockholder Equity76,533,000USD46,094,000USD28,456,000USD28,672,000USD31,727,000USD16,424,000USD20,445,000USD27,178,000USD
    Other Current Liab8,121,000USD7,817,000USD9,493,000USD7,337,000USD6,481,000USD6,133,000USD4,415,000USD4,444,000USD
    Common Stock79,000USD77,000USD75,000USD74,000USD68,000USD62,000USD60,000USD55,000USD
    Capital Stock79,000USD77,000USD75,000USD74,000USD68,000USD———
    Retained Earnings-164,528,000USD-181,910,000USD-190,460,000USD-185,493,000USD-168,953,000USD-141,825,000USD-121,900,000USD-89,753,000USD
    Cash64,788,000USD44,508,000USD27,173,000USD20,289,000USD28,019,000USD16,497,000USD18,612,000USD22,416,000USD
    Cash And Short Term Investments64,788,000USD44,508,000USD27,173,000USD20,289,000USD28,019,000USD16,497,000USD18,612,000USD22,416,000USD
    Total Current Assets96,806,000USD64,102,000USD49,534,000USD46,567,000USD48,905,000USD32,219,000USD33,518,000USD36,534,000USD
    Total Current Liabilities19,919,000USD17,948,000USD20,622,000USD17,869,000USD17,613,000USD16,476,000USD15,063,000USD14,440,000USD
    Net Debt-61,971,000USD-41,857,000USD-23,896,000USD-16,032,000USD-23,317,000USD-14,860,000USD-16,893,000USD-22,106,000USD
    Short Term Debt1,002,000USD994,000USD702,000USD696,000USD548,000USD620,000USD853,000USD173,000USD
    Short Long Term Debt Total2,817,000USD2,651,000USD3,277,000USD4,257,000USD4,702,000USD1,637,000USD1,719,000USD310,000USD
    Net Receivables9,741,000USD7,768,000USD5,234,000USD8,482,000USD5,226,000USD2,694,000USD2,175,000USD4,415,000USD
    Inventory20,424,000USD9,192,000USD14,525,000USD14,677,000USD13,601,000USD11,683,000USD11,535,000USD8,249,000USD
    Accounts Payable10,796,000USD8,526,000USD10,232,000USD9,679,000USD10,423,000USD9,445,000USD9,626,000USD9,548,000USD
    Property Plant Equipment Net3,515,000USD3,449,000USD4,537,000USD6,322,000USD7,355,000USD4,432,000USD4,656,000USD3,585,000USD
    Property Plant Equipment Gross9,269,000USD9,213,000USD9,947,000USD10,876,000USD11,899,000USD———
    Accumulated Other Comprehensive Income-9,000USD-4,000USD-4,000USD-3,000USD-2,000USD-3,000USD——
    Common Stock Shares Outstanding85,436,000shares79,724,500shares74,985,000shares69,729,000shares67,185,000shares61,067,000shares57,056,000shares55,006,000shares
    Non Current Assets Total9,600,000USD4,176,000USD5,430,000USD7,490,000USD8,935,000USD6,139,000USD6,729,000USD5,698,000USD
    Non Current Liabilities Total9,954,000USD4,236,000USD5,886,000USD7,516,000USD8,500,000USD5,458,000USD4,739,000USD614,000USD
    Non Currrent Assets Other425,000USD368,000USD383,000USD497,000USD723,000USD625,000USD762,000USD566,000USD
    Net Working Capital76,887,000USD46,154,000USD28,912,000USD28,698,000USD31,292,000USD———
    Unclassified Non Current Liabilities9,954,000USD4,236,000USD5,886,000USD7,516,000USD8,500,000USD5,458,000USD4,739,000USD—
    Unclassified Equity240,912,000USD227,854,000USD218,770,000USD214,020,000USD200,546,000USD158,190,000USD142,285,000USD116,876,000USD
    Current Deferred Revenue—611,000USD195,000USD157,000USD161,000USD278,000USD169,000USD275,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income6,318,000USD4,132,000USD4,578,000USD3,609,000USD5,063,000USD7,179,000USD1,878,000USD-15,000USD
    Depreciation291,000USD368,000USD359,000USD355,000USD368,000USD358,000USD366,000USD370,000USD
    Stock Based Compensation1,716,000USD1,748,000USD1,756,000USD1,488,000USD1,075,000USD752,000USD735,000USD1,185,000USD
    Other Non Cash Items-4,400,000USD-1,900,000USD3,000USD102,000USD-1,370,000USD-4,900,000USD13,000USD33,000USD
    Change To Account Receivables-3,412,000USD-1,262,000USD1,162,000USD-2,693,000USD2,037,000USD642,000USD710,000USD-1,226,000USD
    Change To Inventory-3,573,000USD-2,036,000USD-4,385,000USD-3,221,000USD-1,993,000USD1,352,000USD967,000USD984,000USD
    Change In Working Capital-5,119,000USD-3,669,000USD-3,004,000USD-4,304,000USD2,747,000USD5,194,000USD503,000USD-1,837,000USD
    Total Cash From Operating Activities-1,194,000USD679,000USD3,692,000USD1,250,000USD7,883,000USD8,583,000USD3,495,000USD-264,000USD
    Capital Expenditures-61,000USD-101,000USD-24,000USD-135,000USD-32,000USD-69,000USD-41,000USD-12,000USD
    Free Cash Flow-1,255,000USD578,000USD3,668,000USD1,115,000USD7,851,000USD8,514,000USD3,454,000USD-276,000USD
    Total Cashflows From Investing Activities5,245,000USD-101,000USD-24,000USD-135,000USD-32,000USD-69,000USD-21,000USD-12,000USD
    Net Borrowings0USD-2,000USD-4,000USD-3,000USD-3,000USD-2,000USD-4,000USD—
    Total Cash From Financing Activities-2,290,000USD-80,000USD148,000USD3,743,000USD3,105,000USD3,748,000USD1,039,000USD596,000USD
    Sale Purchase Of Stock-2,354,000USD-251,000USD——0USD———
    Change In Cash1,761,000USD498,000USD3,816,000USD4,858,000USD10,956,000USD12,262,000USD4,513,000USD320,000USD
    Begin Period Cash Flow64,788,000USD64,290,000USD60,474,000USD55,616,000USD44,660,000USD32,398,000USD27,885,000USD27,565,000USD
    End Period Cash Flow66,549,000USD64,788,000USD64,290,000USD60,474,000USD55,616,000USD44,660,000USD32,398,000USD27,885,000USD
    Other Cashflows From Financing Activities-47,000USD-306,000USD—-6,000USD-6,000USD-41,000USD1,043,000USD598,000USD
    Unclassified Investing Cash Flow5,306,000USD———————
    Investments——-24,000USD-135,000USD-32,000USD-69,000USD-21,000USD-12,000USD
    Unclassified Financing Cash Flow———3,752,000USD3,114,000USD3,791,000USD——
    Other Cashflows From Investing Activities——————20,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income17,382,000USD8,550,000USD-4,938,000USD-16,540,000USD-27,128,000USD-19,925,000USD-32,147,000USD-33,316,000USD
    Depreciation1,450,000USD1,484,000USD1,705,000USD1,884,000USD1,626,000USD1,513,000USD1,523,000USD842,000USD
    Stock Based Compensation6,067,000USD3,656,000USD4,751,000USD5,739,000USD6,195,000USD6,936,000USD7,172,000USD6,371,000USD
    Other Non Cash Items-3,166,000USD-4,715,000USD977,000USD-167,000USD-124,000USD-204,000USD2,586,000USD4,000USD
    Change To Account Receivables-756,000USD-1,279,000USD2,255,000USD-3,319,000USD-2,578,000USD-555,000USD-44,000USD1,111,000USD
    Change To Inventory-11,635,000USD5,333,000USD152,000USD-1,076,000USD-1,918,000USD-148,000USD-3,286,000USD-2,453,000USD
    Change In Working Capital-8,295,999USD3,134,000USD4,622,000USD-6,014,000USD-4,732,000USD1,080,000USD427,000USD5,191,000USD
    Total Cash From Operating Activities13,437,000USD12,109,000USD7,117,000USD-15,098,000USD-24,163,000USD-10,600,000USD-20,439,000USD-20,908,000USD
    Capital Expenditures-292,000USD-163,000USD-148,000USD-334,000USD-409,000USD-142,000USD-753,000USD-1,452,000USD
    Free Cash Flow13,145,000USD11,946,000USD6,969,000USD-15,432,000USD-24,572,000USD-10,742,000USD-21,192,000USD-22,360,000USD
    Total Cashflows From Investing Activities-292,000USD-143,000USD-143,000USD-334,000USD-409,000USD-165,000USD-249,000USD-1,775,000USD
    Net Borrowings-12,000USD-11,000USD-15,000USD-16,000USD-31,000USD———
    Total Cash From Financing Activities6,983,000USD5,369,000USD-90,000USD7,654,000USD36,094,000USD8,650,000USD16,884,000USD-90,000USD
    Sale Purchase Of Stock-251,000USD0USD—————-404,000USD
    Change In Cash20,128,000USD17,335,000USD6,884,000USD-7,778,000USD11,522,000USD-2,115,000USD-3,804,000USD-22,773,000USD
    Begin Period Cash Flow44,660,000USD27,325,000USD20,441,000USD28,219,000USD16,697,000USD18,812,000USD22,616,000USD45,389,000USD
    End Period Cash Flow64,788,000USD44,660,000USD27,325,000USD20,441,000USD28,219,000USD16,697,000USD18,812,000USD22,616,000USD
    Unclassified Financing Cash Flow7,246,000USD5,432,000USD———4,584,000USD16,496,000USD—
    Investments—-143,000USD-143,000USD-334,000USD-409,000USD———
    Other Cashflows From Investing Activities—20,000USD5,000USD——-41,000USD494,000USD-454,000USD
    Other Cashflows From Financing Activities—-52,000USD-75,000USD-77,000USD9,385,000USD4,066,000USD388,000USD510,000USD
    Issuance Of Capital Stock——0USD7,747,000USD26,740,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30SegmentAnalytical Reference Standards And Services0USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentConsumer Products24,162,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentCorporate And Reconciling Items236,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentIngredients5,387,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentPharmaceuticals0USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentAnalytical Reference Standards And Services423,000USD0001386570-26-000030
    Q1 2026Quarterly · 2026-03-31SegmentConsumer Products22,413,000USD0001386570-26-000030
    Q1 2026Quarterly · 2026-03-31SegmentCorporate And Reconciling Items74,000USD0001386570-26-000030
    Q1 2026Quarterly · 2026-03-31SegmentIngredients8,564,000USD0001386570-26-000030
    Q1 2026Quarterly · 2026-03-31SegmentPharmaceuticals0USD0001386570-26-000030
    FY 2025Yearly · 2025-12-31SegmentAnalytical Reference Standards And Services3,076,000USD0001386570-26-000013
    FY 2025Yearly · 2025-12-31SegmentConsumer Products97,672,000USD0001386570-26-000013
    FY 2025Yearly · 2025-12-31SegmentIngredients28,675,000USD0001386570-26-000013
    FY 2025Yearly · 2025-12-31SegmentPharmaceuticals0USD0001386570-26-000013
    Q3 2025Quarterly · 2025-09-30SegmentAnalytical Reference Standards And Services772,000USD0001386570-25-000020
    Q3 2025Quarterly · 2025-09-30SegmentConsumer Products26,017,000USD0001386570-25-000020
    Q3 2025Quarterly · 2025-09-30SegmentIngredients7,197,000USD0001386570-25-000020
    Q2 2025Quarterly · 2025-06-30SegmentAnalytical Reference Standards And Services799,000USD0001386570-25-000010
    Q2 2025Quarterly · 2025-06-30SegmentConsumer Products22,699,000USD0001386570-25-000010
    Q2 2025Quarterly · 2025-06-30SegmentIngredients7,619,000USD0001386570-25-000010
    Q1 2025Quarterly · 2025-03-31SegmentAnalytical Reference Standards And Services811,000USD0001386570-26-000030
    Q1 2025Quarterly · 2025-03-31SegmentConsumer Products21,501,000USD0001386570-26-000030
    Q1 2025Quarterly · 2025-03-31SegmentIngredients8,169,000USD0001386570-26-000030
    Q1 2025Quarterly · 2025-03-31SegmentPharmaceuticals0USD0001386570-26-000030
    FY 2024Yearly · 2024-12-31SegmentAnalytical Reference Standards And Services3,011,000USD0001386570-26-000013
    FY 2024Yearly · 2024-12-31SegmentConsumer Products76,772,000USD0001386570-26-000013
    FY 2024Yearly · 2024-12-31SegmentIngredients19,814,000USD0001386570-26-000013
    FY 2024Yearly · 2024-12-31SegmentPharmaceuticals0USD0001386570-26-000013
    Q3 2024Quarterly · 2024-09-30SegmentAnalytical Reference Standards And Services784,000USD0001386570-25-000020
    Q3 2024Quarterly · 2024-09-30SegmentConsumer Products18,123,000USD0001386570-25-000020
    Q3 2024Quarterly · 2024-09-30SegmentIngredients6,673,000USD0001386570-25-000020
    Q2 2024Quarterly · 2024-06-30SegmentAnalytical Reference Standards And Services791,000USD0001386570-25-000010
    Q2 2024Quarterly · 2024-06-30SegmentConsumer Products18,647,000USD0001386570-25-000010
    Q2 2024Quarterly · 2024-06-30SegmentIngredients3,301,000USD0001386570-25-000010
    Q1 2024Quarterly · 2024-03-31SegmentAnalytical Reference Standards And Services714,000USD0001628280-25-023127
    Q1 2024Quarterly · 2024-03-31SegmentConsumer Products17,351,000USD0001628280-25-023127
    Q1 2024Quarterly · 2024-03-31SegmentIngredients4,088,000USD0001628280-25-023127

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.